The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

I wasn't convinced. That moment led me to a series of tests, where I was ultimately diagnosed with an aggressive cancer and told that I would need chemo, followed by optional mastectomy and ...

Kay, a medical secretary from Dartford, is undergoing chemotherapy and has seen her energy levels fluctuate. Martyn said: "Running the London Marathon has always been on Kay’s ‘bucket list.’ ...

The video was posted alongside the handwritten letter in which she refers to herself as 'the chemo ninja' and requests her favourite band, the Imagine Dragons, come and perform at the Racecourse.

Kiyosaki further remarked, “The chemo is more painful than the cancer,” stressing that job cuts are necessary to address deeper systemic issues. The 77-year-old businessman added ...

Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...

This study aims to evaluate the efficacy and safety of sintilimab in combination with chemotherapy as a neoadjuvant therapy for ESCC. Results: From November 2020 through November 2022, 29 patients ...

The vast majority of Medicare's top-selling brand-name oncology drugs in 2022 provided high added therapeutic benefit. Ten drugs were classified as low or no added therapeutic benefit compared ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945’s potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...

and cemiplimab (Libtayo), an anti–PD-1 agent, in patients with advanced melanoma. 1 The first-in-human, phase 1, open-label, dose-escalation and cohort expansion trial sought to evaluate the safety ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo. The company ...